Dr. Leisha Emens is a professor of medicine, director of translational immunotherapy for the Women’s Cancer Research Center, and co-leader of the Cancer Immunology and Immunotherapy Program at the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center. She received her M.D. and Ph.D. in the Medical Scientist Training Program at Baylor College of Medicine and completed postgraduate training at the National Cancer Institute, the University of Texas at Southwestern, and Johns Hopkins University. She joined the faculty at Johns Hopkins University in 2001, where she rose to the rank of associate professor of oncology before joining the UPMC Hillman Cancer Center. Dr. Emens is a medical oncologist focused on breast cancer and is internationally recognized for her work in breast cancer immunotherapy. She developed a breast cancer vaccine and has recently played a key role in the development of the anti-PD-L1 agent atezolizumab, resulting in accelerated FDA approval for use in advanced triple-negative breast cancer. She currently serves as vice president of the Society for Immunotherapy of Cancer and section editor for the Journal for the Immunotherapy of Cancer. She is also a member of AACR’s Cancer Immunology Steering Committee. She has received much recognition for her work, including the President’s Award by the YWCA of Greater Baltimore, the Maryland Governor’s Citation, and the Sy Holzer Immunotherapy Research Award.